As one of the many physicians who has seen patients harmed by misleading television advertisements, I urge policymakers to make this the year they rein in “bad drug” ads.
The pandemic has forced many Americans to re-examine their approach to life’s challenges and identify ways to be more efficient in changing times. The same should apply to treating people who live with diabetes.
I have been a doctor for 35 years and I have seen a lot of crises. But I have never seen the country’s health care resources strained the way they are right now.
An updated label from the Food and Drug Administration now discourages pharmacies from dividing prepackaged cartons into individual pens before distributing.
A new report from the Institute for Clinical and Economic Review says oral semaglutide treatment for people with Type 2 diabetes isn’t cost effective.
Just one thing stands between some Type 2 diabetes patients and disease management: a dislike of needles.
People living with diabetes might soon have better access to care thanks to an unlikely source: the Internal Revenue Service.
Medicaid’s efforts to save a buck could cost diabetes patients in a big way.